Abstract
Objective: This retrospective study aimed to compare the ability to classify tumor characteristics of breast cancer (BC) of positron emission tomography (PET)-derived texture features between dedicated breast PET (dbPET) and whole-body PET/computed tomography (CT).Methods: Forty-four BCs scanned by both high-resolution ring-shaped dbPET and whole-body PET/CT were analyzed. The primary BC was extracted with a standardized uptake value (SUV) threshold segmentation method. On both dbPET and PET/CT images, 38 texture features were computed; their ability to classify tumor characteristics such as tumor (T)-category, lymph node (N)-category, molecular subtype, and Ki67 levels was compared. The texture features were evaluated using univariate and multivariate analyses following principal component analysis (PCA). AUC values were used to evaluate the diagnostic power of the computed texture features to classify BC characteristics.Results: Some texture features of dbPET and PET/CT were different between Tis-1 and T2-4 and between Luminal A and other groups, respectively. No association with texture features was found in the N-category or Ki67 level. In contrast, receiver-operating characteristic analysis using texture features' principal components showed that the AUC for classification of any BC characteristics were equally good for both dbPET and whole-body PET/CT.Conclusions: PET-based texture analysis of dbPET and whole-body PET/CT may have equally good classification power for BC.
Highlights
Due to the recent advances in breast cancer (BC) treatment, neo-adjuvant systemic chemotherapy is often performed before surgery
Receiver-operating characteristic analysis using texture features’ principal components showed that the area under the curve (AUC) for classification of any BC characteristics were good for both Dedicated Breast Positron Emission Tomography (dbPET) and whole-body positron emission tomography (PET)/computed tomography (CT)
Of 50 BCs that could be detected by both dbPET and whole-body positron emission tomography/computed tomography (PET/CT), 6 [ductal carcinoma in situ (DCIS): 1; T1b: 4; and T1c: 1] could not be successfully extracted with PET/CT
Summary
Due to the recent advances in BC treatment, neo-adjuvant systemic chemotherapy is often performed before surgery. For this reason, PET is widely used for benign vs malignant lesion differentiation, staging, recurrence diagnosis, and prediction of prognosis in various types of cancer, including BC [1]. In more recent years, the performance of whole-body PET/CT scanners has increased along with their diagnostic ability in local evaluation due to the widespread use of devices using time-of-flight (TOF) or point-spread-function (PSF) methods for image reconstruction [3]. By using the two devices in combination, it has been possible to accurately and more rapidly evaluate local and metastatic BC lesions
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have